Imugene Limited Stock Performance
| IUGNF Stock | USD 0.23 0.01 4.55% |
On a scale of 0 to 100, Imugene holds a performance score of 5. The company retains a Market Volatility (i.e., Beta) of 1.1, which attests to a somewhat significant risk relative to the market. Imugene returns are very sensitive to returns on the market. As the market goes up or down, Imugene is expected to follow. Please check Imugene's value at risk and the relationship between the expected short fall and period momentum indicator , to make a quick decision on whether Imugene's current trending patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Imugene Limited are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Imugene reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 29.5 M | |
| Total Cashflows From Investing Activities | -221 K |
Imugene |
Imugene Relative Risk vs. Return Landscape
If you would invest 19.00 in Imugene Limited on September 27, 2025 and sell it today you would earn a total of 4.00 from holding Imugene Limited or generate 21.05% return on investment over 90 days. Imugene Limited is currently producing 0.644% returns and takes up 8.6083% volatility of returns over 90 trading days. Put another way, 77% of traded pink sheets are less volatile than Imugene, and 88% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Imugene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Imugene's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Imugene Limited, and traders can use it to determine the average amount a Imugene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0748
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IUGNF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Imugene is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Imugene by adding it to a well-diversified portfolio.
Imugene Fundamentals Growth
Imugene Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Imugene, and Imugene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Imugene Pink Sheet performance.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.21 | |||
| Profit Margin | (2.92) % | |||
| Operating Margin | (2.91) % | |||
| Current Valuation | 737.79 M | |||
| Shares Outstanding | 6.42 B | |||
| Price To Book | 8.51 X | |||
| Price To Sales | 61.84 X | |||
| Revenue | 12.97 M | |||
| EBITDA | (37.56 M) | |||
| Cash And Equivalents | 99.89 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 673.43 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (30.85 M) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 147.61 M | |||
About Imugene Performance
By analyzing Imugene's fundamental ratios, stakeholders can gain valuable insights into Imugene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Imugene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Imugene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia. Imugene is traded on OTC Exchange in the United States.Things to note about Imugene Limited performance evaluation
Checking the ongoing alerts about Imugene for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Imugene Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Imugene Limited is way too risky over 90 days horizon | |
| Imugene Limited has some characteristics of a very speculative penny stock | |
| Imugene Limited appears to be risky and price may revert if volatility continues | |
| Imugene Limited has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 12.97 M. Net Loss for the year was (37.87 M) with profit before overhead, payroll, taxes, and interest of 12.97 M. | |
| Imugene Limited has accumulated about 99.89 M in cash with (30.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 15.0% of the company shares are held by company insiders |
- Analyzing Imugene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Imugene's stock is overvalued or undervalued compared to its peers.
- Examining Imugene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Imugene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Imugene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Imugene's pink sheet. These opinions can provide insight into Imugene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Imugene Pink Sheet analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |